Prelude Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PRT12396, a mutant‑selective JAK2V617F inhibitor designed to treat myeloproliferative neoplasms such as polycythemia vera and myelofibrosis. The clearance allows the company to begin a Phase 1, open‑label, multi‑center safety and efficacy study in patients with high‑risk polycythemia vera and intermediate‑ or high‑risk myelofibrosis, with the first patient expected to be dosed in the second quarter of 2026.
PRT12396 targets the JAK2V617F mutation, which drives disease progression in the majority of MPN patients. By selectively inhibiting the mutant enzyme, the drug aims to reduce mutant allele burden and slow or reverse disease progression while potentially offering a better safety profile than non‑selective JAK inhibitors currently on the market.
The Phase 1 study will enroll patients across multiple centers, employing an open‑label design to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. The trial’s initiation marks a critical transition from preclinical development to human testing, a milestone that can accelerate the company’s path to regulatory approval and commercialization.
Prelude’s JAK2 program is supported by an exclusive option agreement with Incyte, announced in November 2025. Under the agreement, Incyte provided a $35 million upfront payment and retains the option to acquire the program, underscoring external validation of the drug’s potential and providing a financial cushion for further development.
CEO Kris Vaddi emphasized the strategic importance of the clearance, stating, “The FDA’s clearance of our IND for PRT12396 marks a pivotal first milestone in the strategic transformation and development focus on our JAK2 and KAT6 programs. This achievement demonstrates our ability to translate high‑quality science rapidly into clinical progress and our clear focus on executing these programs that represent the potential to reshape the treatment landscape for the target patient populations.” The announcement was well received by investors, reflecting confidence in Prelude’s pipeline and its partnership with Incyte.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.